To determine the therapeutic efficacy and safety of risk-adapted stereotactic body radiation therapy (SBRT) schedules for patients with early-stage central and ultracentral inoperable non-small cell lung cancer. From 2006 to 2015, 80 inoperable T1-2N0M0 NSCLC patients were treated with two median dose levels: 60 Gy in six fractions (range, 48-60 Gy in 4-8 fractions) prescribed to the 74% isodose line (range, 58%-79%) for central lesions (ie within 2 cm of, but not abutting, the proximal bronchial tree; n = 43), and 56 Gy in seven fractions (range, 48-60 Gy in 5-10 fractions) prescribed to the 74% isodose line (range, 60%-80%) for ultra-central lesions (ie abutting the proximal bronchial tree; n = 37) on consecutive days. Primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), tumor local control rate (LC), and toxicity. Median OS and PFS were 64.47 and 32.10 months (respectively) for ultra-central patients, and not reached for central patients. Median time to local failure, regional failure, and any distant failures for central versus ultra-central lesions were: 27.37 versus 26.07 months, 20.90 versus 12.53 months, and 20.85 versus 15.53 months, respectively, all P < .05. Multivariate analyses showed that tumor categorization (ultra-central) and planning target volume ≥52.76 mL were poor prognostic factors of OS, PFS, and LC, respectively (all P < .05). There was one grade 5 toxicity; all other toxicities were grade 1-2. Our results showed that ultra-central tumors have a poor OS, PFS, and LC compared with central patients because of the use of risk-adapted SBRT schedules that allow for equal and favorable toxicity profiles. K E Y W O R D S efficacy, non-small cell lung cancer, risk-adapted stereotactic body radiation therapy, safety, ultra-central tumor
| INTRODUC TI ON
Stereotactic body radiation therapy (SBRT) delivers an ablative dose to the tumor with a sharp dose fall off that minimizes dose to surrounding critical normal structures. 1 SBRT is a treatment option for peripheral early-stage non-small cell lung cancer (NSCLC) with clinical outcomes comparable to surgery. 2, 3 However, not only optimal dose-fractionation schedules, but also safety and efficacy for central early-stage NSCLC with SBRT are not yet clear, in part because there are varying definitions of "central" tumors. 4, 5 Radiation Therapy Oncology Group (RTOG) 0236 defines a "central" tumor as being within 2 cm of the proximal bronchial tree (PBT), including the carina, right and left main bronchi, and bronchial tree to the second bifurcation. 6 Importantly, central and peripheral tumors were treated with doses used for peripheral lesions, and excessive toxicity was noted primarily among patients with central lesions. 7 Subsequently, RTOG 0813 defines a "central" tumor as being from RTOG0236, and adds tumors that are immediately adjacent to mediastinal or pericardial pleura. RTOG 0813 evaluated the safety and efficacy of SBRT to lesions near the central "no-fly zone". 8 Phase I data from this trial showed a maximum tolerated dose of 60 Gy/5 fractions 9 ;
phase II data reported tumor local control rate (LC), progression-free survival (PFS), and overall survival (OS) at 2 years of 87.9%, 54.5%, and 72.7%, respectively. 10 Although these control rates are encouraging, even conservative dose-fractionation schemes from these trials have been shown to cause severe damage to bronchial structure, bronchial necrosis, and fatal hemoptysis in approximately 5% of patients. 11, 12 In the 2010s, a new subgroup within the cohort of patients with central tumors was designated as "high-risk" or "ultra-central" tumors, or those that abut the PBT. 7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Ultra-central tumors have increased grade 4+ toxicity, even with conservative radiotherapy fractionation. 25 Of concern, Haseltine et al reported that in patients with PBT-abutting tumors who received conservative dose-fractionation SBRT plus bevacizumab, two patients experienced grade 5 pulmonary hemorrhages. 23 Thus, there is great interest in defining risk-adapted dose-fractionation schedules for "high-risk/ultra-central" and "standard-risk/central" early-stage NSCLC. 19, 33 In the present study, we report our experience with risk-adapted SBRT for central and ultra-central early-stage inoperable NSCLC. Our hypothesis is that those with ultra-central tumors have poorer OS, PFS, LC, or higher toxicity rates than those with central tumors. The results of this study may provide clinical guidance in the use of SBRT for early-stage NSCLC patients, and they may be used to interpret the results from the RTOG 0813, 34, 35 EORTC LungTech, 36 and SUNSET 18 prospective clinical trials. It would be very interesting if these studies subdivided their results into central and ultra-central tumors. 
| MATERIAL S AND ME THODS

| Study design and eligible patients
| Stereotactic body radiation therapy treatment schedule, organs at risk contouring and normal tissue constraints
Treatments were carried out using the CyberKnife (CK; Accuray Inc.), a robotic image-guided radiosurgical system, equipped with Synchrony (Accuray Inc.) on consecutive days, which allowed respiratory motion tracking during irradiation. Briefly, CK treatment involves fiducial placement, CT simulation, target volume delineation, treatment planning, and normal tissue constraints.
| Fiducial placement
Patients had one gold fiducial (gold seeds 3 × 0.8 mm; Best Medical International) implanted inside or near the treatment target for targeting purposes in real time. Patients with contraindications to fiducials (eg high-risk pneumothorax, anticoagulant use) were treated with the fiducial-free Xsight (Accuray Inc.) spine-tracking system.
| Computed tomography simulation
Patients were immobilized using a vacuum bag, and a CT was obtained after injection of i.v. radiographic contrast to highlight the tumor. CT simulation was carried out approximately 7 days after fiducial placement to avoid fiducial migration. In the case of Xsight, four-dimensional CT (4-D CT) allowed visible tumor position verification of its range of motion.
| Target volume delineation
Gross tumor volume (GTV) was defined as tumor disease based on simulation, CT, and +/− PET-CT. Planning target volume (PTV) was defined as GTV with the appropriate margin in the x-, y-, and z-axis direction, which was obtained by detection of the motion of gold fiducial markers. If patients were treated with the Xsight spine-tracking system, internal target volume (ITV) was defined as the GTV with the appropriate margins obtained by 4-D CT detection of the motion of the lesions, and then expanded by 5 mm to generate the PTV.
| Treatment planning
A treatment plan was generated based on tumor geometry and location. Plans were optimized and dose calculations were carried out using the ray-tracing dose calculation algorithm. Heterogeneity correction using appropriate CT density models were applied for dose calculation.
| Organs at risk, normal tissue constraints, and biologically effective doses
Organs at risk contouring was adopted from RTOG 0813, 35 EORTC LungTech, 36 SUNSET, 18 and RTOG 1106 contouring atlas, 37 and normal tissue constraints were adopted from RTOG 0813 and previous HILUS studies. 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Meanwhile, maximum point dose and volumetric maximum dose analyses were evaluated for OAR including esophagus, heart, pulmonary artery, pulmonary vein, spinal cord, ipsilateral lung, contralateral lung, lung total, trachea, mainstem bronchi, lobe bronchi, and proximal bronchial tree. Treated doses were converted to biologically effective doses (BED) based on the formula: nd [1 + d/(α/β)], where n is number of fractions, and d is dose/fraction (Gy); assuming α/β value of 10 for NSCLC (ie BED 10 ) and α/β value of 3 for normal tissues (ie BED 3 ). >2.5 or >3 HRF without PET-CT. 38 Regional failure was defined as tumor regrowth in the hilar, mediastinal, or supraclavicular lymph nodes or at the bronchial margin of SBRT, as visualized by CT and/ or PET-CT scanning by independent oncologist and radiologist who were blinded to the treatment to ensure accuracy and precision of the data. Recurrences beyond these sites were deemed distant failures.
| Follow up and endpoints
| Statistical analysis
The 
| RE SULTS
| Patient characteristics
| Overall survival, PFS, and LC
In Figure 2A- In Figure 2A,D, the 1, 3 
| Patterns of failure
Patterns of failure are summarized in Figure 3 
| Prognostic factors associated with OS, PFS and LC
On multivariate analyses, PTV volume and tumor categorization were statistically significant prognostic factors for OS, PFS, and LC, respectively (all P < .05, Table 3 ).
| Toxicities
Toxicity analysis between ultra-central patients and central patients are presented in Table 4 . 
| Dosimetric evaluation
Dosimetric details are summarized in Table S2 . Doses to the esophagus, PBT, main bronchus, lobar bronchus, and contralateral lung dosimetry were higher in the ultra-central group than in the central group because the ultra-central tumor is closer to the mediastinum. However, there were no significant differences in spinal cord, heart, trachea, pulmonary artery, pulmonary vein, total lung, and ipsilateral lung dosimetry between the two groups. In addition, patients who had grade 2 bronchial occlusion or stenosis were found to have bronchial involvement and several dosimetric differences.
| D ISCUSS I ON
In the present study, we report on our experience in comparing Note: Bold face denotes P value < .05. Synchrony (Accuray Inc.); Xsight (Accuray Inc.). Abbreviations: BED 10 Table S3 ), use of risk-adapted SBRT dose-fractionation regimens, and different follow-up schedules in these studies. Intriguingly and importantly, our findings concurred with published data that showed that conservative dose-fractionation schedules for central lesions reduced toxicities at the expense of worse efficacy. [39] [40] [41] At the time of last follow up, our study corroborated with other studies showing that the majority of patients ultimately die of systemic disease progression. 42, 43 However, adjuvant treatment such as chemotherapy, molecular targeted therapy, or biotherapy after SBRT for these patients was undoubtedly understudied and potentially underused. In the present study, only 14 (14/80, 17.5%), five (5/80, 6.3%), and seven (7/80, 8.8%) patients received chemotherapy, molecular targeted therapy, or biotherapy, respectively, after SBRT. Few studies suggest that the treatment strategy of SBRT following chemotherapy is associated with improved PFS and OS for patients with early-stage NSCLC. 44, 45 However, recent studies showed that adjuvant chemotherapy following definitive SBRT is not associated with survival and reduced regional-distant failure benefits for patients with early-stage NSCLC. 45, 46 Unfortunately, a prospective study evaluating the addition of chemotherapy to SBRT in early-stage NSCLC (NCT02319889) has been terminated due to lack of funding. Together, these previous findings indicate that adjuvant treatment after SBRT remains poorly understood and warrants fur- 47 It is worth noting that only one patient died from radiation pneumonitis after SBRT. This patient had interstitial lung disease (ILD) for 15 years and had a bilateral lung V20 of 13.28%; thus, the cause of death was likely a combination of cancer, underlying comorbidities, and toxicity of SBRT.
Radiation pneumonitis is the most frequent toxicity observed after SBRT, and the reported incidence of radiation pneumonitis after SBRT in this study was parallel with those reported in other studies ranging from 10% to 30%. 48 Pre-existing ILD is thought to be a risk factor for fatal radiation pneumonitis after SBRT and, accordingly, severe ILD was regarded as a relative contraindication in the clinical guidelines for SBRT published by the Japanese Society for Therapeutic Radiation and Oncology. 49 Therefore, further studies are necessary to show that prescreening for ILD is important for predicting the risk of radiation pneumonitis when planning SBRT. 
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